Adult-onset spinal muscular atrophy Archives

source: pixabay.com

Risdiplam Delivers An Improvement to Infants with Spinal Muscular Atrophy Type 1

Post author:Rose Duesterwald
Post published:January 29, 2020
Post category:Adult-onset spinal muscular atrophy Spinal muscular atrophy type I with congenital bone fractures

Genentech (Roche Group) announced positive results of its FIREFISH trial in a recent Business Wire news release. The second part of the study evaluated risdiplam’s efficacy on infants ages one…

Clinical Trials Show Promising Results for Risdiplam in Treatment of Spinal Muscular Atrophy Types 1, 2, and 3

Post author:Rose Duesterwald
Post published:October 9, 2019
Post category:Adult-onset spinal muscular atrophy Spinal Muscular Atrophy Spinal muscular atrophy type I with congenital bone fractures

According to a recent article in SMA News Today, risdiplam (formerly RG7916) is in ongoing studies of patients with spinal muscular atrophy (SMA). The drug is an investigational medicine developed by Genentech…

Risdiplam Delivers An Improvement to Infants with Spinal Muscular Atrophy Type 1

Clinical Trials Show Promising Results for Risdiplam in Treatment of Spinal Muscular Atrophy Types 1, 2, and 3

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

“Shades of Psoriasis”: Plaque Psoriasis and Sharing Your Story

Understanding RSV: Why Combatting Ethnic and Age-Related Health Disparities Could Improve Outcomes

We Need Equity and Diversity Within Rare Disease Research

DNA in Color: How Ronya Nelson is Working to Close the Diversity Gap in Genetics - Part 1

Bridging the Diversity Gap in Healthcare

Congratulations to the 2023 Recipients of the Diversity in Lupus Research Awards!

Welcome to Study of the Week. We go in-depth and select a study we think is of particular interest, discussing details, explaining its importance, who may be impacted and lots more!

Let’s Work Together!

Keep Up to Date

Learn More